| 10 |
Bylicki O, Paleiron N, Assié JB, et al. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date [J]. OncoTargets Ther, 2020, 13: 5691-5706.
|
| 11 |
Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable [J]. Lung Cancer, 2017, 103: 27-37.
|
| 12 |
Le X, Heymach JV. New verse for a familiar song: small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer [J]. Oncologist, 2020, 25(10): 822-825.
|
| 13 |
尹利梅, 卢铀. MET 14外显子跳跃突变在非小细胞肺癌中的研究进展 [J]. 中国肺癌杂志, 2018, 21(7): 553-559.
|
| 14 |
Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer [J]. J Hematol Oncol, 2019, 12(1): 63.
|
| 15 |
Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors [J]. Ann Oncol, 2018, 29(suppl_1): 10-19.
|
| 16 |
Scagliotti GV, Shuster D, Orlov S, et al. Tivantinib in combination with Erlotinib versus Erlotinib alone for EGFR-Mutant NSCLC: an exploratory analysis of the phase 3 MARQUEE study [J]. J Thorac Oncol, 2018, 13(6): 849-854.
|
| 17 |
Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer [J]. Ann Oncol, 2020, 31(4) :507-516.
|
| 18 |
Yin W, Cheng J, Tang Z, et al. MET amplification (MET/CEP7 Ratio ≥1.8) is an independent poor prognostic marker in patients with treatment-naive non-small-cell lung cancer [J]. Clin Lung Cancer, 2021, 22(4): 512-518.
|
| 19 |
Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis [J]. Onco Targets Ther, 2020, 13: 2491-2510.
|
| 20 |
Miranda O, Farooqui M, Siegfried JM. Status of agents targeting the HGF/c-Met axis in lung cancer [J]. Cancers (Basel), 2018, 10(9): 280.
|
| 21 |
Salgia R. MET in lung cancer: biomarker selection based on scientific rationale [J]. Mol Cancer Ther, 2017, 16(4): 555-565.
|
| 22 |
Hong L, Zhang J, Heymach JV, et al. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer [J]. Ther Adv Med Oncol, 2021, 13: 1758835921992976.
|
| 23 |
Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase Ⅱ, prospective, multicenter, two-arms trial [J]. Clin Cancer Res, 2019, 25(24): 7312-7319.
|
| 24 |
Markham A. Tepotinib: first approval [J]. Drugs, 2020, 80(8): 829-833.
|
| 25 |
Seto T, Ohashi K, Sugawara S, et al. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study [J]. Cancer Sci, 2021, 112(4): 1556-1566.
|
| 26 |
Dhillon S. Capmatinib: first approval [J]. Drugs, 2020, 80(11) :1125-1131.
|
| 27 |
Vansteenkiste JF, Van De Kerkhove C, Wauters E, et al. Capmatinib for the treatment of non-small cell lung cancer [J]. Expert Rev Anticancer Ther, 2019, 19(8): 659-671.
|
| 28 |
Huang C, Zou Q, Liu H, et al. Management of non-small cell lung cancer patients with MET exon 14 skipping mutations [J]. Curr Treat Options Oncol, 2020, 21(4): 33.
|
| 29 |
Lu S, Fang J, Li X, et al. Once-daily Savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study [J]. Lancet Respir Med, 2021. doi: 10.1016/S2213-2600(21)00084-9. Online ahead of print. |
| 30 |
Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma [J]. Curr Opin Oncol, 2020, 32(4) : 321-331.
|
| 31 |
韩森, 马旭, 方健. 非小细胞肺癌MET基因突变的机制及靶向药物研究进展 [J]. 中国肺癌杂志, 2020, 23(7): 609-614..
|
| 32 |
Piper-Vallillo AJ, Halbert BT, Rangachari D, et al. Acquired resistance to Osimertinib plus Savolitinib is mediated by MET-D1228 and MET-Y1230 mutations in EGFR-mutated MET-amplified lung cancer [J]. JTO Clin Res Rep, 2020, 1(4): 100071.
|
| 1 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update [J]. Discov Med, 2019, 27(148): 167-170.
|
| 2 |
Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) [J]. Respirology (Carlton, Vic.), 2015, 20(3): 370-378.
|
| 3 |
Aoki MN, Amarante MK, de Oliveira CEC, et al. Biomarkers in non-small cell lung cancer: perspectives of individualized targeted therapy [J]. Anticancer Agents Med Chem, 2018, 18(15): 2070-2077.
|
| 4 |
Santarpia M, Massafra M, Gebbia V, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations [J]. Transl Lung Cancer Res, 2021, 10(3): 1536-1556.
|
| 5 |
Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer [J]. Expert Opin Investig Drugs, 2018, 27(4):363-375.
|
| 6 |
Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer [J]. Int J Mol Sci, 2021, 22(5): 2625.
|
| 7 |
Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy, Nature reviews [J]. Clin Oncol, 2020, 17(9) :569-587.
|
| 8 |
Drilon A, Cappuzzo F, Ou SI, et al. Targeting MET in lung cancer: will expectations finally be MET? [J]. J Thorac Oncol, 2017, 12(1): 15-26.
|
| 9 |
俞晓晴, 徐艳珺, 范云. c-MET通路和抑制剂在非小细胞肺癌中的研究进展 [J]. 中国肺癌杂志, 2017, 20(4): 287-292.
|